Cradle-to-Grave Emission Reduction for Easyhaler Dry Powder Inhaler Product Portfolio.

IF 2.3 Q2 RESPIRATORY SYSTEM Pulmonary Therapy Pub Date : 2023-12-01 Epub Date: 2023-09-25 DOI:10.1007/s41030-023-00239-7
Matleena Inget, Hanna Hisinger-Mölkänen, Myles Howard, Satu Lähelmä, Noora Paronen
{"title":"Cradle-to-Grave Emission Reduction for Easyhaler Dry Powder Inhaler Product Portfolio.","authors":"Matleena Inget, Hanna Hisinger-Mölkänen, Myles Howard, Satu Lähelmä, Noora Paronen","doi":"10.1007/s41030-023-00239-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>There is increasing pressure to prefer propellant-free inhaler devices over pressurized metered-dose inhalers (pMDI) due to environmental considerations. In this work, we present results from three life cycle assessments (LCAs) on Easyhaler dry powder inhaler product portfolio and assess the changes in environmental impact and carbon footprint (CF) of the products over time.</p><p><strong>Methods: </strong>Three cradle-to-grave LCAs were conducted in 2019, 2021, and 2023. The 2019 assessment covered four products while 2021 and 2023 assessments included all six products in the portfolio. LCA for the protective cover sometimes used with Easyhaler was conducted in 2023. In addition to CF, nine other environmental impact categories were assessed to ensure that no burden shifting occurs.</p><p><strong>Results: </strong>During the study period, the non-weighted average CF of the Easyhaler decreased by 11.2%. For individual products, the decrease varied from 5.0 to 6.8% between the assessments. In the latest assessment, the average CF of Easyhaler was 547 gCO<sub>2</sub>e with a range of 452-617 gCO<sub>2</sub>e. The LCA of the protective cover was assessed for the first time in 2023 and had a CF of 66 gCO<sub>2</sub>e.</p><p><strong>Conclusions: </strong>Our results show that the climate impact of pharmaceutical products can be reduced without making changes to the product itself. The CF of Easyhaler products is in agreement with the lower end of the CF range previously reported for dry powder inhalers. Climate impact from the protective cover was one-tenth compared to the climate impact from the product itself.</p>","PeriodicalId":20919,"journal":{"name":"Pulmonary Therapy","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10721773/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pulmonary Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s41030-023-00239-7","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/9/25 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: There is increasing pressure to prefer propellant-free inhaler devices over pressurized metered-dose inhalers (pMDI) due to environmental considerations. In this work, we present results from three life cycle assessments (LCAs) on Easyhaler dry powder inhaler product portfolio and assess the changes in environmental impact and carbon footprint (CF) of the products over time.

Methods: Three cradle-to-grave LCAs were conducted in 2019, 2021, and 2023. The 2019 assessment covered four products while 2021 and 2023 assessments included all six products in the portfolio. LCA for the protective cover sometimes used with Easyhaler was conducted in 2023. In addition to CF, nine other environmental impact categories were assessed to ensure that no burden shifting occurs.

Results: During the study period, the non-weighted average CF of the Easyhaler decreased by 11.2%. For individual products, the decrease varied from 5.0 to 6.8% between the assessments. In the latest assessment, the average CF of Easyhaler was 547 gCO2e with a range of 452-617 gCO2e. The LCA of the protective cover was assessed for the first time in 2023 and had a CF of 66 gCO2e.

Conclusions: Our results show that the climate impact of pharmaceutical products can be reduced without making changes to the product itself. The CF of Easyhaler products is in agreement with the lower end of the CF range previously reported for dry powder inhalers. Climate impact from the protective cover was one-tenth compared to the climate impact from the product itself.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Easyhaler干粉吸入器产品组合从摇篮到坟墓的减排。
简介:出于环境考虑,人们越来越倾向于使用无推进剂吸入器设备,而不是加压计量吸入器。在这项工作中,我们介绍了Easyhaler干粉吸入器产品组合的三个生命周期评估(LCA)结果,并评估了产品随时间的变化对环境的影响和碳足迹。方法:在2019年、2021年和2023年进行了三次从摇篮到坟墓的LCA。2019年的评估涵盖了四种产品,而2021年和2023年的评估包括了投资组合中的所有六种产品。对Easyhaler有时使用的防护罩进行LCA是在2023年进行的。除CF外,还评估了其他九个环境影响类别,以确保不会发生负担转移。结果:在研究期间,Easyhaler的非加权平均CF下降了11.2%。对于单个产品,评估之间的下降幅度从5.0%到6.8%不等。在最新评估中,Easyhaler的平均CF为547 gCO2当量,范围为452-617 gCO2当量。2023年首次评估了保护套的生命周期评价,其CF为66 gCO2e。结论:我们的研究结果表明,在不改变产品本身的情况下,可以减少药品对气候的影响。Easyhaler产品的CF与之前报道的干粉吸入器CF范围的低端一致。与产品本身的气候影响相比,防护罩对气候的影响是十分之一。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Pulmonary Therapy
Pulmonary Therapy Medicine-Pulmonary and Respiratory Medicine
CiteScore
5.20
自引率
3.30%
发文量
24
审稿时长
6 weeks
期刊介绍: Aims and Scope Pulmonary Therapy is an international, open access, peer-reviewed (single-blind), and rapid publication journal. The scope of the journal is broad and will consider all scientifically sound research from pre-clinical, clinical (all phases), observational, real-world, and health outcomes research around the use of pulmonary therapies, devices, and surgical techniques. Areas of focus include, but are not limited to: asthma; chronic obstructive pulmonary disease; idiopathic pulmonary fibrosis; pulmonary hypertension; cystic fibrosis; lung cancer; respiratory tract disorders; allergic rhinitis and other respiratory allergies; influenza, pneumococcal infection, respiratory syncytial virus and other respiratory infections; and inhalers and other device therapies. The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/series, trial protocols and short communications such as commentaries and editorials. Pulmonary Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals. Rapid Publication The journal’s publication timelines aim for a rapid peer review of 2 weeks. If an article is accepted it will be published 3–4 weeks from acceptance. The rapid timelines are achieved through the combination of a dedicated in-house editorial team, who manage article workflow, and an extensive Editorial and Advisory Board who assist with peer review. This allows the journal to support the rapid dissemination of research, whilst still providing robust peer review. Combined with the journal’s open access model this allows for the rapid, efficient communication of the latest research and reviews, fostering the advancement of pulmonary therapies. Open Access All articles published by Pulmonary Therapy are open access. Personal Service The journal’s dedicated in-house editorial team offer a personal “concierge service” meaning authors will always have an editorial contact able to update them on the status of their manuscript. The editorial team check all manuscripts to ensure that articles conform to the most recent COPE, GPP and ICMJE publishing guidelines. This supports the publication of ethically sound and transparent research. Digital Features and Plain Language Summaries Pulmonary Therapy offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by key summary points, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand the scientific content and overall implications of the article. The journal also provides the option to include various types of digital features including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations. All additional features are peer reviewed to the same high standard as the article itself. If you consider that your paper would benefit from the inclusion of a digital feature, please let us know. Our editorial team are able to create high-quality slide decks and infographics in-house, and video abstracts through our partner Research Square, and would be happy to assist in any way we can. For further information about digital features, please contact the journal editor (see ‘Contact the Journal’ for email address), and see the ‘Guidelines for digital features and plain language summaries’ document under ‘Submission guidelines’. For examples of digital features please visit our showcase page https://springerhealthcare.com/expertise/publishing-digital-features/ Publication Fees Upon acceptance of an article, authors will be required to pay the mandatory Rapid Service Fee of €4500/ $5100/ £3650. The journal will consider fee discounts and waivers for developing countries and this is decided on a case by case basis. Peer Review Process Upon submission, manuscripts are assessed by the editorial team to ensure they fit within the aims and scope of the journal and are also checked for plagiarism. All suitable submissions are then subject to a comprehensive single-blind peer review. Reviewers are selected based on their relevant expertise and publication history in the subject area. The journal has an extensive pool of editorial and advisory board members who have been selected to assist with peer review based on the afore-mentioned criteria. At least two extensive reviews are required to make the editorial decision, with the exception of some article types such as Commentaries, Editorials, and Letters which are generally reviewed by one member of the Editorial Board. Where reviewer recommendations are conflicted, the editorial board will be contacted for further advice and a presiding decision. Manuscripts are then either accepted, rejected or authors are required to make major or minor revisions (both reviewer comments and editorial comments may need to be addressed). Once a revised manuscript is re-submitted, it is assessed along with the responses to reviewer comments and if it has been adequately revised it will be accepted for publication. Accepted manuscripts are then copyedited and typeset by the production team before online publication. Appeals against decisions following peer review are considered on a case-by-case basis and should be sent to the journal editor. Preprints We encourage posting of preprints of primary research manuscripts on preprint servers, authors’ or institutional websites, and open communications between researchers whether on community preprint servers or preprint commenting platforms. Posting of preprints is not considered prior publication and will not jeopardize consideration in our journals. Authors should disclose details of preprint posting during the submission process or at any other point during consideration in one of our journals. Once the manuscript is published, it is the author’s responsibility to ensure that the preprint record is updated with a publication reference, including the DOI and a URL link to the published version of the article on the journal website. Please follow the link for further information on preprint sharing: https://www.springer.com/gp/authors-editors/journal-author/journal-author-helpdesk/submission/1302#c16721550 Copyright Pulmonary Therapy''s content is published open access under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information about the Creative Commons Attribution-Noncommercial License, click here: http://creativecommons.org/licenses/by-nc/4.0. Contact For more information about the journal, including pre-submission enquiries, please contact christopher.vautrinot@springer.com.
期刊最新文献
Perspectives on Drug Product Design Among Patients with Lung Cancer in the United Kingdom. Efficacy of High Flow Nasal Cannula in the Treatment of Patients with COVID-19 with Acute Respiratory Distress Syndrome: Results of Single Centre Study in Vietnam. Expert Panel Consensus Recommendations for Allergic Rhinitis in Patients with Asthma in India. Survival Outcomes in US Medicare Patients with Non-Cystic Fibrosis Bronchiectasis by Rate of Baseline Exacerbations. Patient Profile-Based Management with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1